TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...
The pembrolizumab regimen reduced the risk of disease progression or death by 28% and reduced the risk of death by 24% compared with placebo plus paclitaxel with or without bevacizumab. The Food and ...
Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. Perioperative therapy may ...
Periop enfortumab vedotin plus pembrolizumab shows strong efficacy in phase 3 trials of cisplatin-eligible and cisplatin-ineligible MIBC. Perioperative enfortumab vedotin plus pembrolizumab (EV+P) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results